PTGS2 and leukemia: To summarize, our results on two established medulloblastoma cell lines – Daoy and D283 Med – confirmed our previous findings in leukemia and neuroblastoma cells that the differentiating effects of ATRA should be enhanced in its combined administration with caffeic acid (an inhibitor of 5-LOX) or celecoxib (an inhibitor of COX-2).